Full Press Release Details
DUBLIN , July 22, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2014 second quarter financial results on Tuesday, August 5, 2014 , after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT / 9:30 p.m. IST to provide a business and financial update and discuss second quarter 2014 financial results.
Interested parties may access the live audio webcast via the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com . Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for one week.
Audio webcast/conference call: U.S. Dial-In Number: +1 866 277 1184 International Dial-In Number: +1 617 597 5360 Passcode: 29980973
A replay of the conference call will be available through August 12, 2014 and accessible through one of the following telephone numbers and entering the passcode:
Replay U.S. Dial-In Number: +1 888 286 8010 Replay International Dial-In Number: +1 617 801 6888 Passcode: 13741471
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. The company has a diverse portfolio of products and/or product candidates in the areas of sleep, hematology/oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi ), Prialt® (ziconotide) intrathecal infusion, Versacloz® (clozapine) oral suspension, FazaClo® (clozapine, USP) HD and FazaClo LD. Jazz Pharmaceuticals also has a number of products marketed outside the U.S., including Erwinase® and Defitelio® (defibrotide). For more information, please visit www.jazzpharmaceuticals.com .
SOURCE Jazz Pharmaceuticals plc